News | June 24, 2022
Silo Pharma expands license agreement and patent portfolio
Silo enters into commercial evaluation license agreement for next generation liposomes
Silo enters into commercial evaluation license agreement for next generation liposomes
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
Bayer now present in four of the largest biotechnology hubs in the United States
The groundbreaking SPF technology is specifically designed and formulated to prevent sunburn or sun damage while allowing the passage of sufficient UVB light that our bodies use to naturally produce vitamin D
Includes thermostabilized Ebola vaccines
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
